Top Markets
Coin of the day
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
株式のランク #13314
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
株価
$0.30780727
時価総額
$94.19M
変化(1日)
-0.19%
変化(1年)
-34.73%
FR
取引 Sensorion SA (ALSEN)

カテゴリー

Sensorion SA(ALSEN)の利益
Dec 2025 時点の利益 TTM: $-40.05M
Sensorion SA の最新の財務報告によると、同社の現在の利益は $-40.05M です。2023 年には $-24.06M の利益を上げ、これは 2022 年の利益 $-29.06M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Sensorion SA の利益の推移(2011 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-40.05M 48.91%
2024 $-26.89M 11.77%
2023 $-24.06M -17.20%
2022 $-29.06M 40.87%
2021 $-20.63M 56.49%
2020 $-13.18M -19.26%
2019 $-16.33M 15.05%
2018 $-14.19M 22.11%
2017 $-11.62M 21.72%
2016 $-9.55M 64.80%
2015 $-5.79M 55.42%
2014 $-3.73M 64.62%
2013 $-2.26M 73.88%
2012 $-1.30M 56.52%
2011 $-832.10K 0.00%
同業他社の利益
企業 利益 利益の差
$24.72B -61,819.42%
DK
$5.17B -12,998.66%
US
$5.16B -12,976.69%
US
$2.14B -5,437.79%
BE
$1.66B -4,233.76%
NL